{
    "title": "GSK notches up a victory in its efforts to develop a vaccine for a common respiratory illness",
    "url": "https://www.dailymail.co.uk/money/markets/article-10904985/Shot-arm-Glaxo-respiratory-jab-breakthrough.html",
    "date": "2022-06-10",
    "keywords": [
        "gsk",
        "share",
        "vaccine",
        "rsv",
        "year",
        "fund",
        "emma",
        "walmsley",
        "jab",
        "executive",
        "data",
        "johnson",
        "boss",
        "money",
        "price",
        "pressure",
        "elliott",
        "investment",
        "account",
        "fee",
        "victory",
        "respiratory",
        "illness",
        "ftse100",
        "pharma",
        "giant",
        "virus",
        "effectiveness",
        "trial",
        "diseasecausing",
        "majority",
        "cause",
        "pneumonia",
        "boost",
        "race",
        "jabs",
        "brummer",
        "splitout",
        "haleon",
        "spinoff",
        "consumer",
        "glaxo",
        "maker",
        "affinivax",
        "deal",
        "article",
        "management",
        "pipeline",
        "approval",
        "half",
        "catalyst",
        "broker",
        "berenberg",
        "competition",
        "company",
        "ability",
        "business",
        "lack",
        "background",
        "announcement",
        "adult",
        "market",
        "drug",
        "companys",
        "diy",
        "capital",
        "risk",
        "isa",
        "trade",
        "month",
        "community",
        "model",
        "affiliate",
        "product",
        "commission",
        "editorial",
        "independence",
        "investing",
        "platform"
    ],
    "category": [
        "money",
        "markets"
    ]
}